title: Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
abstract: OBJECTIVE
  To study the efficacy and tolerance of certolizumab pegol (CZP) in active uveitis.
  
  
  METHODS
  Retrospective case series at 4 referral centers. Patients treated with CZP for active uveitis during at least 6 months were eligible. Inflammation by SUN scores, visual acuity (VA) (logMAR), and central macular thickness (CMT) were compared from baseline until final follow-up. Quiescence was defined as 0+ to 0.5+ in anterior chamber and vitreous haze scores and no CMT increase.
  
  
  RESULTS
  Four males and 3 females (14 eyes) were included, mean age 42.4 ± 8.8 years. All were long-lasting chronic-relapsing uveitis with prior failure to other anti-TNF-α. After a mean follow-up of 10.4 ± 4.8 months, 5/7 patients (71.4%) achieved quiescence with CZP. VA improved significantly from +0.52 ± 0.68 to +0.45 ± 0.68 (p = 0.032) at 1 month and to +0.44 ± 0.64 (p = 0.035) at 6 months. No adverse events were found.
  
  
  CONCLUSIONS
  CZP can be an effective alternative in refractory uveitis.
authors.affiliation: a Clínic Institute of Ophthalmology (ICOF), Hospital Clínic of Barcelona , Barcelona , Spain .
authors.forename: Victor
authors.initials: V
authors.lastname: Llorenç
authors.affiliation: a Clínic Institute of Ophthalmology (ICOF), Hospital Clínic of Barcelona , Barcelona , Spain .
authors.forename: Marina
authors.initials: M
authors.lastname: Mesquida
authors.affiliation: a Clínic Institute of Ophthalmology (ICOF), Hospital Clínic of Barcelona , Barcelona , Spain .
authors.forename: Maite
authors.initials: M
authors.lastname: Sainz de la Maza
authors.affiliation: b Department of Rheumatology , Marqués de Valdecilla Hospital , Santander , Spain .
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.affiliation: b Department of Rheumatology , Marqués de Valdecilla Hospital , Santander , Spain .
authors.forename: Vanesa
authors.initials: V
authors.lastname: Calvo
authors.affiliation: c Department of Rheumatology , Donostia Universitary Hospital , San Sebastián , Spain , and.
authors.forename: Olga
authors.initials: O
authors.lastname: Maíz
authors.affiliation: c Department of Rheumatology , Donostia Universitary Hospital , San Sebastián , Spain , and.
authors.forename: Ana
authors.initials: A
authors.lastname: Blanco
authors.affiliation: d Department of Rheumatology , Txagorritxu Hospital , Vitoria-Gazteiz , Spain.
authors.forename: Juan Ramón
authors.initials: JR
authors.lastname: de Dios-Jiménez de Aberásturi
authors.affiliation: a Clínic Institute of Ophthalmology (ICOF), Hospital Clínic of Barcelona , Barcelona , Spain .
authors.forename: Alfredo
authors.initials: A
authors.lastname: Adán
mesh_terms: D000328:Adult; D000068582:Certolizumab Pegol / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008266:Macula Lutea / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000068582:Certolizumab Pegol
keywords: Anti-TNF; biologics; certolizumab pegol; treatment; uveitis